CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inhibitor Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inhibitor Therapeutics Inc
4830 W. Kennedy Blvd., Suite 600
Phone: (813) 766-2462p:813 766-2462 TAMPA, FL  33609  United States Ticker: INTIINTI
This company was Merged or Acquired on 11/2/2016.
This is a Subsidiary, click here for the Parent Company
Business Summary
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes-Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer Francis E.O'Donnell 73 12/13/2022 12/13/2022
Chief Financial Officer, Treasurer, Secretary James A.Mcnulty 72 12/13/2022 12/13/2022
Director Ronald E.Osman 77 8/23/2023 8/23/2023
4 additional Officers and Directors records available in full report.

Business Names
Business Name
HEDGEPATH PHARMACEUTICALS, INC.
HPPI
INTI
Mimotopes Pty Ltd
Tripos Discovery Research Limited
Tripos Discovery Research Products and Services

General Information
Number of Employees: 3 (As of 12/31/2023)
Outstanding Shares: 172,023,545 (As of 3/29/2024)
Shareholders: 86
Stock Exchange: OTC
Federal Tax Id: 300793665
Fax Number: (813) 527-0500
Email Address: INFO@CBI-BIOTECH.COM


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024